

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/779,767	01/07/1997	HABIB ZAGHOUANI	ALLIA.143A	6240
75	90 05/21/2002			
NED A ISRAELSON			EXAMINER	
KNOBBE MAR 16TH FLOOR	RTENS OLSON AND BE	NOLAN, PATRICK J		
620 NEWPORT	CENTER DRIVE			
NEWPORT BE	ACH, CA 92660	ART UNIT	PAPER NUMBER	
			1644	U2
			DATE MAILED: 05/21/2002	YX

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 08/779,767

Applicant(s)

Zaghouani

Examiner

Patrick J. Nolan

Art Unit 1644



The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
	for Reply						
THE N	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.			<del></del>			
	- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.						
- If the p - If NO p - Failure - Any rep	period for reply specified above is less than thirty (30) days, a reply within the seriod for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) he application to become	) MONTHS tome ABAND	from the mailing date of this communication.  DONED (35 U.S.C. § 133).			
Status							
1) 💢	Responsive to communication(s) filed on <u>Feb 11, 2</u>	2002		·			
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This act	tion is non-final	1.				
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.						
	tion of Claims						
	Claim(s) 4, 6, 9, 11, 24, 26, 27, 29, 66-70, and 7.						
4	a) Of the above, claim(s)			is/are withdrawn from consideration.			
5) 🗔	Claim(s)			is/are allowed.			
	Claim(s) 4, 6, 9, 11, 24, 26, 27, 29, 66-70, and 72						
7) 🗀	Claim(s)			is/are objected to.			
8) 🗆	Claims are subject to restriction and/or election requirement.						
	tion Papers						
9) $\square$ The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) $\square$ The proposed drawing correction filed on is: a) $\square$ approved b) $\square$ disapproved by the Examiner							
_	If approved, corrected drawings are required in reply to this Office action.						
12) $\square$ The oath or declaration is objected to by the Examiner.							
	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some* c) None of:							
	1. U Certified copies of the priority documents have been received.						
	2. Lactified copies of the priority documents have been received in Application No						
<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>*See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
<ul> <li>14)</li></ul>							
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
	cice of References Cited (PTO-892)	4) Interview Sur	mmary (PT(	O-413) Paper No(s)			
2) Not	ice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)					
3) X Information Disclosure Statement(s) (PTO-1449) Paper No(s). 41 6) Other:							

Serial Number: 08/779,767

Art Unit: 1644

## Part III DETAILED ACTION

1. Claims 4, 6, 9, 11, 24, 26-27, 29, 66-70 and 72-74 are pending.

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2-11-02 has been entered.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103<sup>©</sup> and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 4, 6, 9, 11, 24, 26, 27, 29, 66-70 and 72-74 stand rejected under 35 U.S.C. § 103 as being unpatentable over Bona et al. (U) in view of Kuchroo et al. (U), all of record, for reasons stated in Paper Nos. 21, 26, 35 and 39.

Serial Number: 08/779,767

Art Unit: 1644

Applicant's arguments filed 2-11-02 have been fully considered but are not found persuasive.

Applicant's argue that the prevention of T cell activation by their construct is an unexpected result.

However, the unexpected result must be commensurate with the claimed invention. Currently the claimed invention is drawn to any T cell receptor peptide agonist. Furthermore, the unexpected result is limited to preventing T cell activation after in vivo administration of the construct.

It is noted that if applicant was to limit their claimed invention to preventing T cell activation in vivo, with the currently presented claims, and provide evidence in a signed official declaration demonstrating said unexpected result of preventing T cell activation could convey to at least one more biologically distinct peptide antagonist, the rejection under 35 USC 103 would be removed.

- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Tuesday through Friday from 8:30 am to 4:30 pm.
- 5. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7939. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

fatur J. Woh.
Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

May 19, 2002